Processing...
Clinical Trials for Kidney Cancer
Search
Search
There are 146 active trials for advanced/metastatic kidney cancer.
Click on a trial to see more information.
146 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with ECOG 0–1 and measurable advanced selected solid tumors, including SCLC, extrapulmonary high-grade neuroendocrine/small-cell carcinomas, NSCLC, prostate, ovarian, renal, HNSCC, hepatic, gastric, and triple-negative breast cancers, after progression/relapse/intolerance to at least one standard systemic therapy. All patients receive dose-escalated oral EXS74539/REC-4539 monotherapy, a selective reversible LSD1/KDM1A epigenetic inhibitor, to define safety and MTD with preliminary efficacy assessment.
ClinicalTrials.gov ID: NCT07517198
TrialFetch AI summary: Adults with ECOG 0–1 and refractory/relapsed locally advanced unresectable or metastatic solid tumors, including post–PD-1/PD-L1 treated RCC, HCC, gastroesophageal cancer, and endometrial cancer, receive CTX-10726 monotherapy IV every 2 weeks. CTX-10726 is an investigational tetravalent bispecific antibody targeting PD-1 and VEGF-A to combine checkpoint blockade with anti-angiogenic activity.
ClinicalTrials.gov ID: NCT07419841
TrialFetch AI summary: Children and young adults aged 2–39 years with measurable, unresectable recurrent or refractory Wilms tumor or desmoplastic small round cell tumor receive IV trastuzumab deruxtecan every 21 days. Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate that delivers a topoisomerase I inhibitor payload to HER2-expressing tumor cells.
ClinicalTrials.gov ID: NCT04616560
TrialFetch AI summary: Adults with advanced/metastatic clear-cell–component renal cell carcinoma, ECOG 0–1, measurable disease, and ≥50% tumor CAIX expression after prior PD-1/PD-L1 inhibitor and tyrosine kinase inhibitor therapy receive fludarabine/cyclophosphamide lymphodepletion followed by autologous LNK001 CAR-T cells. LNK001 uses a dual-receptor CAIX/ENPP3 Boolean AND-gate designed to activate preferentially against tumor cells coexpressing both targets.
ClinicalTrials.gov ID: NCT07564232
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic clear cell renal cell carcinoma who have exhausted, cannot medically receive, or lack access to standard therapies and have CAIX-positive uptake on PD-32766D PET imaging receive intravenous PD-32766T, an actinium-225–labeled CAIX-targeting peptide that delivers localized alpha radiation. Treatment is dose-escalated and expanded for up to six cycles.
ClinicalTrials.gov ID: NCT07688187
TrialFetch AI summary: Adults with unresectable or metastatic solid tumors after prior immune-checkpoint or related T-cell-directed therapy and appropriate standard therapy may receive oral ARV-6723 alone or with pembrolizumab. ARV-6723 is an investigational PROTAC that degrades HPK1/MAP4K1 to enhance antitumor immune signaling; later cohorts may include investigator-selected standard of care.
ClinicalTrials.gov ID: NCT07749586
TrialFetch AI summary: Adults with unresectable or metastatic hepatocellular carcinoma, or advanced uveal melanoma, renal cell, non-small-cell lung, or colorectal cancer after standard therapy or when standard therapy is inappropriate, receive oral VMD-102 monotherapy. VMD-102 is an investigational selective inhibitor of protein kinase C epsilon (PKCε/PRKCE).
ClinicalTrials.gov ID: NCT07636785
TrialFetch AI summary: Adults with metastatic castration-resistant prostate cancer after at least two systemic treatment lines or metastatic clear-cell renal cell carcinoma progressing after a PD-1/PD-L1–containing regimen receive investigational REGN15505, a PSMA×4-1BB antibody, alone or with cemiplimab (anti-PD-1) or REGN4336 (an investigational PSMA×CD3 T-cell–engaging antibody).
ClinicalTrials.gov ID: NCT07594106
TrialFetch AI summary: Patients with advanced solid tumors after standard therapy has failed or is unsuitable receive intravenous BNT317, an investigational bispecific antibody targeting PD-1 and CD39, in dose escalation. Expansion cohorts evaluate BNT317 alone in previously treated clear-cell renal cell carcinoma and with standard-of-care chemotherapy in previously treated HER2-negative gastric or gastroesophageal-junction cancer and non-small-cell lung cancer without actionable alterations.
ClinicalTrials.gov ID: NCT06750185
TrialFetch AI summary: Adults with previously treated advanced or metastatic solid tumors, ECOG 0–1, measurable disease, and a biopsiable tumor receive intravenous or subcutaneous ST-067, alone, after obinutuzumab pretreatment, or with pembrolizumab. ST-067 is an engineered IL-18 that activates the IL-18 receptor while resisting neutralization by IL-18 binding protein; expansion cohorts focus on melanoma, renal cell, triple-negative breast, non-small cell lung, head and neck squamous cell, and MSI-high cancers.
ClinicalTrials.gov ID: NCT04787042